56201-56-0

Upstream product

• 298-81-7 9-methoxy-7H-furo[3,2-g][1]benzopyran-7-one 
• 7790-94-5 chlorosulfonic acid 
• 482-44-0 imperatorin 
• 2009-24-7 8-hydroxypsoralen 

Downstream Products

• 92831-33-9 9-Methoxy-7-oxo-7H-furo[3,2-g]chromene-4-sulfonic acid (4-hydroxy-phenyl)-amide 
• 92831-20-4 4-(9-Methoxy-7-oxo-7H-furo[3,2-g]chromene-4-sulfonylamino)-benzoic acid 
• 92831-32-8 9-Methoxy-7-oxo-7H-furo[3,2-g]chromene-4-sulfonic acid (3-hydroxy-phenyl)-amide 
• 73166-87-7 9-Methoxy-7-oxo-7H-furo[3,2-g]chromene-4-sulfonic acid benzylamide 
• 92831-48-6 9-Methoxy-7-oxo-7H-furo[3,2-g]chromene-4-sulfonic acid (4-phenylamino-phenyl)-amide 
• 63581-29-3 9-methoxy-7-oxo-7H-furo[3,2-g]chromene-4-sulfonamide 
• 1019709-84-2 C₂₇H₁₆BrClN₂O₇S₂ 
• 1019709-17-1 C₂₁H₁₇NO₈S 
• 1019708-96-3 C₂₀H₁₆N₂O₈S 
• 56201-62-8 (S)-3-(4-Hydroxy-phenyl)-2-(9-methoxy-7-oxo-7H-furo[3,2-g]chromene-4-sulfonylamino)-propionic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of linear furanocoumarins as potential anti-breast and anti-prostate cancer agents

A series of 22 furanocoumarin derivatives were synthesized and evaluated for cytotoxicity against breast cancer (MCF-7 and MDA-MB-231) and prostate cancer (PC-3) cell lines along with normal cell line. Several analogs were synthesized by replacing prenyl moiety with alkyl, aromatic, and heteroaromatic functionality to study the structure-activity relationship. Compounds 20 and 22 with adamantoylamino, diprenylamino and substituted benzene sulfonamide substituents showed potent antiproliferative activity in MCF-7 cell line with IC50 values of 0.48 and 0.53 μM, respectively. Both the compounds showed higher IC50 value in MCF-10A cell lines indicating nontoxicity in normal cell lines.

Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study

Psoralen (1a) was found to be a specific and potent antimicrobial lead against Helicobacter pylori (H. pylori) from a traditional Chinese medicine (TCM) in the bioassay directed isolation. A series of structurally diverse analogues of 1a were thus designed and synthesized to improve the antimicrobial potency, some of which showed more potent activities than the lead compound (1a) against H. pylori. Among them, compound 25a is 16-fold stronger (MIC = 0.39 μg/mL) than 1a (MIC = 6.25 μg/mL), and is even potent than the positive control metronidazole (MIC = 0.50 μg/mL). The in vitro antimicrobial activities against H. pylori of these structurally diverse analogues based on the scaffold of 1a have also led to an outline of structure-activity relationship.